KYLEENA (levonorgestrel) by Bayer. Approved for progestin [epc]. First approved in 2016.
Drug data last refreshed 1h ago · AI intelligence enriched 2d ago
KYLEENA is a levonorgestrel-releasing intrauterine system (IUS) approved in 2016 for contraception. It is a small-molecule progestin delivered directly to the uterus via an intrauterine device, providing long-acting reversible contraception. The device releases levonorgestrel locally to prevent pregnancy through multiple mechanisms including cervical mucus thickening and endometrial suppression.
KYLEENA is at peak lifecycle with modest Part D spending; the brand team is likely focused on defending market position against stronger competitors rather than aggressive expansion.
Progestin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on KYLEENA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
Working on KYLEENA offers limited growth potential given its peak-stage maturity and imminent LOE; roles are primarily defensive and focused on protecting existing market share against intra-portfolio competition and generic entry. Career development is best suited for professionals seeking stability in a mature, specialized contraceptive segment rather than high-growth opportunity.